Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00002662
First received: November 1, 1999
Last updated: August 1, 2013
Last verified: April 2004
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: docetaxel
Drug: paclitaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: August 1994
Study Completion Date: June 2004
Detailed Description:

OBJECTIVES:

  • Compare the response rate in women with metastatic or locally advanced, inoperable adenocarcinoma of the breast treated with docetaxel vs paclitaxel.
  • Compare the toxicity of these regimens in these patients.
  • Compare the time to disease progression, duration of response, quality of life, and survival of patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive paclitaxel IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and after courses 4 and 6.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 400 patients (200 per arm) will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically proven metastatic or locally advanced, inoperable adenocarcinoma of the breast

    • Clinically evident metastases (e.g., clearly malignant lesions on chest x-ray or CT or abdominal CT do not require histologic confirmation)
    • Hot spots on bone scan not shown to be malignant on plain x-rays are not adequate evidence of malignant disease in the absence of other lesions
  • Must meet 1 of the following conditions:

    • Disease progression after 1 prior chemotherapy regimen for locally advanced or metastatic disease (which may or may not have followed a separate adjuvant regimen using chemotherapy or hormonal therapy)
    • Locally advanced or metastatic disease during or after 1 adjuvant or neoadjuvant chemotherapy regimen
    • One of the above chemotherapy regimens must have contained an anthracycline (e.g., doxorubicin, but not mitoxantrone)
    • Single drug substitution (e.g., methotrexate for doxorubicin) during prior combination chemotherapy allowed
  • Bidimensionally measurable
  • No clinical or radiographic evidence of brain or leptomeningeal disease
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Sex:

  • Female

Menopausal status:

  • Not specified

Performance status:

  • Karnofsky 60-100% OR
  • ECOG 0-2

Life expectancy:

  • At least 12 weeks

Hematopoietic:

  • Absolute neutrophil count at least 2,000/mm3
  • Platelet count at least 100,000/mm3

Hepatic:

  • Bilirubin normal
  • SGOT no greater than 2.5 times upper limit of normal

Renal:

  • Creatinine no greater than 2.0 mg/dL
  • No uncontrolled hypercalcemia

Cardiovascular:

  • No myocardial infarction within the past 6 months
  • No history of arrhythmia requiring treatment
  • No heart block
  • No clinical evidence of congestive heart failure
  • No unstable angina (e.g., new onset, crescendo, or rest angina)
  • Stable exertional angina allowed

Other:

  • No current symptomatic grade 2 or greater peripheral neuropathy
  • No history of hypersensitivity to products containing Cremophor EL (e.g., cyclosporine or teniposide) or Polysorbate 80 (e.g., IV etoposide)
  • No serious infection
  • No significant psychiatric disease that would preclude study
  • No other malignancy within the past 5 years except nonmelanomatous skin cancer or completely excised carcinoma in situ of the cervix
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior bone marrow or stem cell transplantation

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy (2 weeks for oral cyclophosphamide or 6 weeks for nitrosoureas or mitomycin)
  • No prior high-dose chemotherapy given with ablative intent
  • No prior taxoids
  • No other concurrent antineoplastic therapy

Endocrine therapy:

  • See Disease Characteristics
  • Prior hormonal therapy as adjuvant therapy or for metastatic disease allowed
  • At least 1 week since prior hormonal therapy
  • No concurrent corticosteroids except:

    • Prophylaxis or treatment for acute hypersensitivity reactions
    • Chronic therapy (more than 6 months) at low doses (20 mg/day or less of methylprednisolone or equivalent)

Radiotherapy:

  • At least 4 weeks since prior radiotherapy to major bone marrow areas
  • No prior high-dose radiotherapy given with ablative intent
  • No concurrent radiotherapy except limited palliative radiotherapy (e.g., for a solitary rib fracture) during objective response

Surgery:

  • See Disease Characteristics
  • More than 2 weeks since prior surgery except simple biopsy or placement of venous access device

Other:

  • At least 4 weeks since prior investigational drugs
  • Concurrent medications known to alter cardiac conduction (e.g., digoxin, beta blockers, or calcium channel blockers) allowed
  • No concurrent ketoconazole
  • No concurrent bisphosphonates unless initiated more than 3 months before randomization
  • No concurrent experimental drug or therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002662

  Show 32 Study Locations
Sponsors and Collaborators
Aventis Pharmaceuticals
Investigators
Study Chair: Peter M. Ravdin, MD The University of Texas Health Science Center at San Antonio
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00002662     History of Changes
Other Study ID Numbers: AVENTIS-56976-TAX-311, CDR0000064232, RP-56976-TAX-311, NCI-V95-0680
Study First Received: November 1, 1999
Last Updated: August 1, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV breast cancer
stage IIIA breast cancer
recurrent breast cancer
stage IIIB breast cancer
stage IIIC breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Docetaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 16, 2014